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The use of transposons as insertional mutagens to
identify cancer genes in mice has generated a wealth
of information over the past decade. Here, we discuss
recent major advances in transposon-mediated
insertional mutagenesis screens and compare this
technology with other screening strategies.paste process (DNA transposons), or through an RNAIntroduction
Genome sequencing has revealed a plethora of muta-
tions in cancer, with some tumors carrying tens of thou-
sands of somatic mutations [1]. Importantly, the
relevance of these mutations is not always intrinsically
clear and as a result must be inferred from the types of
mutations observed, their frequency across tumor types,
and their predicted effects on protein function. Inser-
tional mutagenesis screens provide a functional readout
to complement these sequencing studies, as genes iden-
tified by insertional mutagens are likely to represent
both functionally important and evolutionarily con-
served cancer genes. Insertional mutagenesis studies can
also highlight cancer genes or common pathways that
are disrupted at low frequency or by processes not im-
mediately obvious from the genome sequence alone.
The first insertional mutagenesis efforts in mice were
performed with the murine leukemia virus and the
mouse mammary transforming virus to induce lymph-
oma and mammary tumors [2, 3], respectively, and led
to the identification of numerous cancer pathways,
including the WNT pathway [4]. However, these viruses
were found to be of limited utility for mutagenesis in
other tissue types owing to viral tropism and the fact* Correspondence: fak2009@med.cornell.edu; cw6@sanger.ac.uk
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these retroviruses generate insertions that activate gene
expression, they almost exclusively tag proto-oncogenes
[5], restricting our ability to identify other types of cancer
genes such as tumor suppressors.
For these reasons, DNA transposons were developed
as insertional mutagens [6]. Transposons are mobile
elements that move through the genome by a cut-and-
intermediate in a copy-and-paste mechanism (retrotran-
sposons) [7]. Endogenous transposons are ubiquitous in
vertebrate genomes, comprising approximately 45 % of
DNA sequence [8], but are largely silent as a result of in-
activating mutations acquired through evolution. The
introduction of exogenous DNA transposons allows in-
sertional mutagenesis in a wider spectrum of tissues
than the ones that are accessible with retroviruses, and
thus the generation of new mouse tumor models [9, 10].
The most commonly used transposon systems are the
Sleeping Beauty (SB) and piggyBac (PB) systems [11]. A
typical transposon used for in vivo insertional mutagenesis
contains splice acceptors (SAs) followed by polyadenyla-
tion signals (pA) in both orientations, and a unidirectional
promoter upstream of a splice donor (SD). A transposon
can either disrupt gene function when it integrates into
the body of a gene, thereby intercepting and curtailing
transcription through the SA–pA elements, or it can acti-
vate expression when inserted upstream of a gene as the
promoter–SD module drives expression of downstream
sequences (Fig. 1). The pattern and orientation of trans-
poson integration sites therefore often provide a clue as to
whether the affected gene encodes a tumor suppressor or
an oncogene.
Here, we discuss recent advances in cancer gene
discovery using transposons and their role in the era of
other mutagenesis tools such as clustered regularly inter-
spaced short palindromic repeats/CRISPR-associated
protein 9 (CRISPR/Cas9).le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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Fig. 1 Transposons as insertional mutagens. a Sleeping Beauty (SB) and piggyBac (PB) (black rectangles) are mutagenic transposons that can be
mobilized from donor loci (left panel) and reintegrated into other loci (right panel). Repeats in the transposon (arrowheads) are recognized by the
Sleeping Beauty or piggyBac transposases (ovals), resulting in the transposon being excised from the genome. Reintegration of mobilized SB or PB
transposons can occur at TA and TTAA sites, respectively, catalyzed by transposase activity. b Transposon insertion can promote or disrupt gene
expression. In the example depicted in this panel, a transposon integrates between exons 3 and 4 (numbered gray boxes) of a gene. This can
result in two possible outcomes: (I) the transposon disrupts gene function by hijacking transcription through the splice acceptor-polyadenylation
signal (SA-pA) elements, leading to expression of a truncated transcript (exons 1–3); or (II) the transposon drives expression of the downstream
gene sequences (exons 4–7) through the promoter-splice donor (SD) elements. Depending on the integration site, transposons can activate or
abrogate expression of either the entire mRNA of a gene or only parts of it
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In 2005, the groups of David Largaespada, Nancy
Jenkins and Neal Copeland reported the use of the
Sleeping Beauty transposon system as a tool for the
identification of cancer-promoting genes in transgenic
mice [12, 13]. Largaespada and colleagues performed
whole-body transposon-mediated insertional muta-
genesis (TMIM) with the first-generation T2/Onc
transposon, accelerating tumorigenesis in mice null
for the tumor suppressor p19Arf gene [12]. Using a
more active transposon system (T2/Onc2), Dupuy and
colleagues induced predominantly hematopoietic tumors
following global mutagenesis in wild-type mice [13]. Fol-
lowing these landmark studies, a variety of transgenic
mouse strains harboring different versions of transposons
and transposases have been generated and utilized forcandidate cancer gene discovery. By targeting SB transpo-
sase expression to tissues of interest, a variety of cancers
have been generated by mutagenesis [13–20]. Addition-
ally, several cancer types have been accelerated by TMIM
in combination with sensitizing mutations [21–27, 29, 30]
(Table 1). Collectively, many candidate cancer genes have
been identified in the mouse that have subsequently been
found to be relevant clinically and prognostically in hu-
man malignancies [20, 24] (Table 1). In a similar way, the
PB transposon has been used for cancer gene discovery in
the hematopoietic system and pancreas [31, 32].
TMIM — technical considerations
Various mouse strains have been generated that express
SB or PB transposase in a ubiquitous or conditional
manner. With these strains, transposon mobilization can
Table 1 Capacity of TMIM screens to identify common human cancer genes in three cancer typesa




Comments Novel, functionally validated cancer
genes identified in TMIM screens
Colorectal APC [102] Yes [19, 22, 23, 51] CNOT1, PDE4DIP, PDCD6IP, ATF2,
SFI1 [22]
TP53 [102] Yes (low frequency) [23, 51] Tp53 has been rarely targeted
in any TMIM screen, although
upstream regulators such as
Cdkn2a are frequently targeted
in TMIM screens
ANKRD11, CSNK2A1, MKL2, MYO9A,
RNF43, SIN3A, Zfp292 [51]
KRAS [102] Yes (low frequency) [23, 51] Insertions in Kras have been
detected at low frequency in
Apc-deficient backgrounds [23],
perhaps reflecting the inability
of transposons to cause point
mutations in target genes through
insertion alone. However, upstream
and downstream genes within the
Kras signaling pathway are targeted
in TMIM screens, leading to
pathway activation
PIK3CA [102] No Other phosphoinositide 3-kinase
pathway genes have been
targeted, for example Pik3r1
and Pten
FBXW7 [102] Yes [23, 51]
SMAD4 [102] Yes [23, 51]
CTNNB1 [102] Yes [23, 51]
NRAS [102] No Recurrent insertions in Nras have
not been found, probably owing
to the same reasons applicable
to Kras
TCF7L2 [102] Yes [23, 51]
FAM123B [102] No Other components of Wnt–β-catenin
pathway are targeted in tumors, for
example Apc and Ctnnb1.
Melanoma BRAF [103, 104] Yes [49] Identified as potential mediator
of BRAF inhibitor resistance
ERAS [49]
NRAS [103, 104] No
TP53 [103, 104] No CEP350 [38]
PTEN [103, 104] Yes [38, 49] MAGI2, PTPRO, Map3k1 [57]
CDKN2A [103, 104] Yes [38, 49, 57]
NF1 [103, 104] Yes [38] Melanoma TMIM screens were
performed in a Braf-mutant
background. NF1 mutations are
typically mutually exclusive from
BRAF mutations in human
melanoma, potentially accounting
for the lack of Nf1 insertions in
some screens
RAC1 [103, 104] No Other genes operating in Rho
GTPase pathways have been
targeted
MAP2K1 [103, 104] No Other MAP kinase pathway
genes have been targeted in
melanoma TMIM screens
ARID2 [103, 104] No
PPP6C [103, 104] Yes [38, 49] Identified as potential mediator
of BRAF inhibitor resistance
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Table 1 Capacity of TMIM screens to identify common human cancer genes in three cancer typesa (Continued)
Pancreatic KRAS [105, 106] Yes (low frequency) [24] Pancreatic cancer TMIM screens
were performed in a KrasG12D
background
USP9X [24]
TP53 [105, 106] No Recurrent insertions in Tp53 were
not observed despite the high
prevalence of TP53 alterations in
human pancreatic cancer. Cdkn2a
was a recurrent CIS-associated
gene, and Usp7, a p53-regulatory
deubiquitinase, was targeted at
low frequency in one study [24]
Foxp1, Foxp2, Bcl6, Fign [32]
CDKN2A [105, 106] Yes [24, 32]
SMAD4 [105, 106] Yes [24, 25]
PREX2 [106] No
TGFBR2 [105, 106] Yes [24, 32]
RNF43 [106] Yes [24, 25]
KDM6A [106] Yes [24, 25, 32]
ARID1A [105, 106] Yes [24, 32]
MLL3 [105] Yes [24, 25]
aShown are details of TMIM screens for identifying common human cancer genes in three types of cancer for which more than one screen has been performed.
TMIM transposon-mediated insertional mutagenesis
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temporal-restricted manner by using an appropriate Cre
recombinase allele (Fig. 2). The transposon mice are
transgenic strains containing transposon concatemers on
a single chromosome. As a consequence, many insertion
sites are found locally, and the tendency for local in-
tegrations is reported as being higher with SB
compared with PB [33]. The number of transposons
in the concatemer is also a consideration. Global
mobilization of greater than 20–30 transposon copies
during embryonic development correlated with in-
creased embryonic lethality [13, 15, 31]. Additionally,
increasing transposon numbers amplifies the potential
for passenger integrations, which do not contribute to
the observed phenotype.
The promoter within the transposon can display
tissue-specific activity and thereby influence the pheno-
type of whole-body insertional mutagenesis screens or
the insertion sites that are positively selected for in
organ-specific screens. Indeed, the first transposon
mouse strains (T2/Onc, T2/Onc2) utilized the murine
stem cell virus (MSCV) promoter, which displays a pro-
pensity for the development of hematopoietic tumors.
However, replacing the MSCV promoter with the
chicken β-actin/CMV enhancer (CAG) promoter or the
phosphoglycerate kinase 1 (PGK) promoter significantly
increased the incidence of solid tumors in both the SB
and PB system [14, 31]. Thus, the modularity of transpo-
sons and the ability to modify elements such as the pro-
moters they carry can be used to influence the tumor
type and incidence.An important technical consideration in transposon
screens is integration bias. SB has been reported to dem-
onstrate a bias towards integration into DNA sequences
containing TA nucleotides and appears to preferentially
integrate into gene bodies but not into transcriptional
start sites (TSSs) [34] (Fig. 3). Conversely, PB, which
predominantly integrates into TTAA sequences, displays
a preference towards integration into TSSs over gene
bodies (Fig. 3). As a consequence, oncogenes are more
likely to be identified using PB, whereas transposon
integration in tumor suppressors is primarily seen when
the SB system is used, but this again is influenced by the
promoter elements used in the transposon. Allan Bradley’s
group recently reported the development of a conditional
PB transposase mouse allele [32], which can direct cell- or
tissue-specific expression of PB, and hence directs muta-
genesis to a specific cellular compartment. The develop-
ment of this strain allowed the direct comparison of
screening data generated in a mouse model of KrasG12D-
driven pancreatic cancer, where a prior screen with the SB
transposon system had been performed [24]. The PB
screen identified candidate drivers that had also been
identified by the pancreatic SB screen as well as novel can-
didate pancreatic cancer genes, and thus exemplified the
complementarity of the SB and PB approaches as in vivo
insertional mutagens for cancer gene discovery.
Another consideration that investigators should be
mindful of when performing insertional mutagenesis
screens is the damage done to the genome by the
process of transposition itself as transposons are mobi-













































Fig. 3 Integration biases of SB and PB transposons. The distribution of transposon insertions across genes from 5 kb upstream of the transcription
start site (TSS) to 5 kb downstream of the transcription termination site (TTS). Red, transposon insertions in the sense orientation relative to the
gene; blue, insertions in antisense direction. Reproduced from [34]
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Global mutagenesis Spatiotemporal mutagenesis
Spatiotemporal cooperating
mutagenesis
Transposon T2/Onc series or ATP series T2/Onc series or ATP series T2/Onc series or ATP series
Transposase Constitutive SB or PB Cre-inducible SB or PB Cre-inducible SB or PB
Inducer None
Constitutive or inducible tissue-
specific Cre
Constitutive or inducible tissue-
specific Cre
Cooperator
None or constitutive mutant or
knock-out





SB transposons SB/PB transposons
Constitutive transposase
SA
Fig. 2 Tools for transposon-mediated mutagenesis. a Transposase expression can be either ubiquitous (ub. prom.) or directed to a particular cell
or tissue type by using Cre-inducible alleles of the transposase enzyme. In the latter case, a loxP-site-flanked transcriptional stop element (gray triangles
and STOP sign, respectively) prevents transcription of the gene encoding transposase. Upon Cre-mediated excision of the loxP-STOP-loxP element, the
transposase is expressed in Cre-positive cells. b A variety of transposons have been developed for mutagenesis. SB transposons have been developed
that carry either a murine stem cell virus (MSCV) promoter (T2/Onc and T2/Onc2) or the chicken β-actin/CMV enhancer (CAG) promoter (T2/Onc3). To
facilitate gene activation, transposons carrying these promoters also contain splice donor (SD) elements, and, for gene disruption, splice acceptor (SA)
and polyadenylation (pA) elements (bi-pA bi-directional polyadenylation signal). Versatile SB/PB transposons containing terminal repeats recognized by
SB and PB transposases (arrowheads) have also been developed and carry either CAG, MSCV or mouse phosphoglycerate kinase 1 (PGK) promoters
(ATP1, ATP2 and ATP3 transposons, respectively). c Using combinations of the aforementioned alleles tabulated here, global or spatiotemporal
mutagenesis with co-operating mutations can be performed
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the genome; by contrast, the mobilization of SB transpo-
sons leaves behind a two-to-five nucleotide footprint
[35]. SB transposon footprints can thus result in frame-
shift mutations, splicing alterations or promoter disrup-
tions, which in turn could promote tumorigenesis. The
mobilization of transposons in cis could also result in
chromosomal rearrangements such as deletions or copy-
number-neutral changes [36]. Fortunately, these passen-
ger effects appear to be limited [36–38], and thus tumor
promotion in transposon screens appears to be largely
driven by transposon insertion events, but this factor is
nevertheless of consideration in the analysis of tumors
collected during screening.
TMIM — statistical considerations
Although tumor evolution selects for mutagenic inser-
tions that drive tumorigenesis, each tumor cell will
harbor multiple additional inconsequential passenger in-
sertions, as repeated rounds of transposon mobilization
and reintegration will result in thousands of integration
sites in a polyclonal tumor. Cancer drivers cannot be
identified solely by sequencing all of the insertion sites
in a given tumor — this merely gives a snapshot of
insertion sites at a point in time. Thus, statistical ap-
proaches are necessary to reveal regions of the genome
that are enriched with insertions more than expected by
chance — so-called common insertion sites (CISs). By
mapping CISs onto a reference genome, CIS-associated
genes can be identified as potential cancer drivers.
A number of statistical approaches have been used to
identify CIS-associated genes from transposon screens.
Early studies deployed Monte Carlo-based methods and
Poisson distributions [39, 40] to define those genomic
locations enriched with insertion sites. More recently,
Gaussian Kernel Convolution (GKC) approaches [41],
gene-centric common insertion site (gCIS) analysis [42]
and refined versions of the Poisson approach have been
developed [43]. Essentially, all these methods provide a
measure of the degree to which insertion sites are
enriched at a given locus relative to either a pre-
computed background distribution or an insertion data-
set derived from tissues in which transposons have been
mobilized for a short period of days or weeks, before
clonal selection could be operative. The concordance
between methods ranges between 60 and 80 %, and thus
most investigators use multiple algorithms to identify
CISs [23]. Methods such as GKC [41] adjust the signifi-
cance statistic for a locus (CIS) relative to the frequency
of the transposon target site (TA for SB, and TTAA for
PB) that can account for some local biases in transposon
integration. Both the type and stringency of the CIS-calling
methods used to identify insertions affect the classification
of co-occurring or mutually exclusive CISs. Reinders andcolleagues have developed a two-dimensional GKC method
to identify co-operating mutations from virally in-
duced mutagenesis data, a method that has also been
applied to TMIM screens [44]. In addition, the Poisson
regression insertion model (PRIM) [45] has been used to
identify co-occurring gene pairs, and the TAPDANCE al-
gorithm can generate the association of independent CISs
by using a Fisher’s exact test [43].
Limitations of TMIM
TMIM is a powerful tool for in vivo cancer gene discov-
ery, but, as with every technology, there are several limi-
tations. We summarize these limitations here and also
allude to them throughout the text. The primary limita-
tion is the inability of the transposons to interrogate the
genome in a completely unbiased fashion. Transposons
do not integrate into and affect all genes with similar
probability owing to factors such as promoter selection
within the transposon [31], integration-site preferences
[34], local transposon hopping [33], gene size (larger
genes are more likely to be affected by transposon inte-
grations) and the relative superior ease of isolating
tumor suppressors as the precise transposon integration
site and orientation with respect to the target gene are
less crucial factors for tumor suppressors compared with
those of oncogenes.
Another limitation is that TMIM cannot recapitulate
the complete spectrum of mutations that are commonly
found in human cancer, such as point mutations.
Elevated expression and mutations may not result in
identical biological outcomes, and thus transposon-
mediated overexpression of proto-oncogenes does not
always mimic the effects of somatic, gain-of-function
point mutations [46]. Similarly, mutations in tumor sup-
pressors can result in dominant-negative effects that are
not recapitulated by transposon-insertion-mediated loss
of expression [47]. The insertion spectrum recovered by
TMIM screens can also be affected by the sensitizing
genetic backgrounds that activate pro-tumorigenic path-
ways — for example, oncogenic mutants of B-Raf or
Kras [24, 32, 38, 48, 49], such that genes that activate
the same pathway as the sensitizing mutation are un-
likely to be identified in these particular backgrounds.
Finally, transposon insertions are unable to recapitulate
reciprocal translocations such as BCR–ABL and other
genomic alterations that commonly occur in cancer.
There are also technical and resource limitations to
TMIM approaches. For example, investigators might
wish to perform drop-out screens designed to identify
genes that are detrimental to cells when mutated. Such
screens are not feasible with TMIM as such cells are lost
during the screening process. Moreover, the generation
of mouse cohorts is both time-consuming and costly for
in vivo TMIM screens as compound mutant mice
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required. Finally, candidate cancer genes identified
through TMIM screens in the mouse might not necessar-
ily have equal relevance in human cancer— follow-up val-
idation studies must therefore be performed. Investigators
should consider all these limitations when designing
transposon screens.
Transposon mutagenesis— beyond the basic
screen
Over the past decade, numerous TMIM studies have
identified known and novel cancer genes that either
promote tumor initiation or co-operate with cancer-
sensitizing mutations to drive tumor progression. Re-
cently, novel and elegant ways of employing transposon
mutagenesis to query specific cancer processes have
been devised. In this section, we summarize recent de-
velopments in the TMIM field.
Investigating tumor progression and evolution
TMIM screens have been performed in mice harboring
various initiating mutations found in human cancer.
Such screens identify drivers of tumor progression and,
importantly, might be influenced by the sensitizing mu-
tation. For example, Alexander and colleagues per-
formed TMIM in the hematopoietic system, which
resulted in multiple leukemias [50]. A Jak2V617F-mutant
background skewed the disease towards erythroleuke-
mia, and insertions in the ETS transcription factor genes
Erg and Ets1 were identified as the most common
events. Conversely, when using an activated ERG allele
(TLS-ERG) as the sensitizing mutation, the authors iden-
tified frequent activating insertions in Jak2, thus validat-
ing the co-operation between Jak2 and Erg [50].
In an elegant study, TMIM was utilized to delineate
evolutionary events during the progression of colorectal
cancer (CRC) [51]. Jenkins, Copeland and colleagues
crossed the SB system into different sensitizing back-
grounds that carry mutations in genes that act at different
stages of CRC: Apcmin, KrasG12D, Smad4+/− or Tp53R172H
(Fig. 4) [51]. Intriguingly, this approach revealed that func-
tional loss of the wild-type Apc allele was the most crucial
event for tumor progression in Apcmin, KrasG12D and
Tp53R172H tumors, but not in tumors that were initiated
by heterozygous loss of Smad4. Instead, those tumors dis-
played frequent insertions in the wild-type Smad4 allele
along with mutually exclusive insertions in Rspo1 and
Rspo2 that promoted overexpression of these R-spondins,
which are known enhancers of Wnt signaling. In addition,
111 candidate cancer genes were identified that were
independent of the initiating mutation.
These studies illustrate how sensitizing mutations can
co-operate with transposon-associated lesions and how
different pre-existing mutations can sometimes influencethe trajectory of subsequent mutation acquisition during
tumor development. In the case of human CRC, loss
of APC is thought to be the initiating event, whereas
mutations in KRAS, TP53 or SMAD4 occur later dur-
ing tumor progression. Indeed, transposon-insertion-
mediated loss of Apc appeared to be a prerequisite
for colon tumorigenesis in the Apcmin, KrasG12D and
Tp53R172H backgrounds, whereas insertions in Kras
and Tp53 are rare in Apc-loss-driven CRC [51]
(Table 1; Fig. 4). This finding further supports the no-
tion of APC being the gatekeeper of CRC. Conversely,
leukemogenesis is initiated by either mutant Jak2 or
Erg and progresses upon transposon insertions in the
other gene, suggesting that the temporal sequence of
mutation might be irrelevant [50]. Taken together,
TMIM is a valuable tool to delineate tumor progression,
and future studies that unravel the genetic dependencies
of co-operating mutations on different initiating muta-
tions in other cancer types will shed further light on the
genetics of tumor progression and might be useful for de-
vising treatment strategies.
Determining the evolutionary history of mutations
within tumors can inform our understanding of the mu-
tational forces that shape cancer development. To assess
tumor clonality in a more quantitative fashion, new
methods to estimate the frequency of transposon inser-
tions in tumors have been devised. Historical methods
to retrieve insertion sites have been based primarily on
PCR amplification of restriction-endonuclease-digested,
adaptor-ligated tumor DNA, followed by high-throughput
sequencing. However, sequence coverage cannot be used
to infer tumor clonality accurately owing to PCR biases as
a result of the variable distribution of restriction enzyme
sites in the genome. An alternative approach, called shear-
splink, was developed by Jonkers and colleagues that frag-
ments DNA by acoustic shearing, mitigating this bias [52].
In addition, as DNA is fragmented at random, each frag-
ment harbors a potentially unique stretch of DNA that
can serve as a molecular barcode. Quantification of
these barcodes permits estimation of transposon
clonality within a heterogeneous sample. Rad and
colleagues used a similar approach, termed quantita-
tive insertion site sequencing (QIseq), to illustrate
the marked genetic complexity of pancreatic tumors
[32]. Although these approaches can estimate transposon
clonality, they cannot distinguish between transposon het-
erogeneity arising during tumor evolution in a monoclo-
nal sample and multiple distinct insertions in a polyclonal
tumor population.
Identifying genes involved in metastasis
In addition to identifying genes involved in tumor initiation
and progression, TMIM has been performed to discover
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Fig. 4 Use of transposon-mediated insertional mutagenesis (TMIM) screening to identify mutations that co-operate with specific genetic lesions
associated with different stages of colorectal cancer development. The top panels illustrate a model of colorectal cancer initiation and progression
[101], along with genetic alterations associated with these stages. TMIM screens using mouse models carrying mutations in corresponding genes
have revealed that Apc was the predominant gene inactivated in tumors from all sensitizing genotypes apart from Smad4KO/+ cases, where
inactivation of the remaining wild-type Smad4 gene is the most frequent insertional event
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osteoblasts and identified candidate genes involved in
metastasis by comparing transposon insertions from
osteosarcoma metastases with those found in primary
tumors [53]. Approximately one-third of CIS-associated
genes found in metastases were evident in primary
tumors. Furthermore, from this analysis, five candidate
oncogenes and 38 tumor suppressors were identified,
including nine genes that have been implicated previously
in cancer metastasis. To study further the evolutionary
relationships between metastases and parental ancestors,
the authors conducted parsimony analysis of tumors using
transposon integration sites as molecular footprints.
Osteosarcoma metastases were found to be highly clonal
but appeared to show different patterns of evolution from
the primary tumor.
Taylor and colleagues performed a TMIM screen
aimed at identifying genes affecting dissemination of
medulloblastoma in Ptch1+/− heterozygous null or
mutant Tp53 mouse backgrounds [54]. Interestingly, the
authors found that both transposon-driven mouse and
human metastatic medulloblastoma are clonal but diver-
gent from the primary tumor, suggesting that only a rare
subclone in the primary tumor is able to metastasize.
Four of the identified candidate genes were validated asdrivers of medulloblastoma dissemination by retroviral
delivery of these candidates to the cerebellum in com-
bination with overexpression of the Ptch1 ligand sonic
hedgehog (Shh) [55]. These studies demonstrated the
utility of TMIM screens to discover drivers of metastatic
spread, and further studies will identify candidate metas-
tasis genes in certain genetic backgrounds and tumor
types. Some mouse cancer models might not be suitable
for identification of metastasis genes by TMIM because
the mice have to be sacrificed before the formation of
macroscopic metastases owing to the primary tumor
size. However, surgical removal of the primary tumor to
allow more time for metastasis growth or transplant-
ation of primary tumor cells into syngeneic wild-type
mice could circumvent this issue. Nonetheless, these re-
ports illustrate how TMIM can be employed to query
the clonal relationship of a primary tumor and its metas-
tases, complementing the use of transposons to identify
genes involved in tumor progression.
Identifying alterations in cancer pathways
Apart from identifying genes promoting tumor progres-
sion, TMIM screens have been used to define the most
prominent signaling pathways deregulated in tumors.
Using the TAPDANCE tool, Largaespada and colleagues
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Tp53-mutant, EGFR-driven peripheral nerve sheath tu-
mors to identify roles for the phosphoinositide 3-kinase
(PI3K)-AKT-mTOR, mitogen-activated protein kinase
(MAPK) and Wnt/β-catenin pathways in the development
of this tumor type [56]. Novel pathways have also been re-
vealed in melanoma driven by oncogenic B-RafV600E. Xu
and colleagues identified a network involving Magi2 with
a PB screen at low transposon copy number and also
found insertions in Map3k1 and Map3k2 that resulted in
ERK activation [57]. However, these insertions occurred in
melanomas that had not recombined the conditional
oncogenic B-RafV600E allele. Although not examined, this
suggests that aberrant MAP3K1/MAP3K2 activation
could represent another means to activate the MAPK
pathway in human melanoma besides the common BRAF
and NRAS mutations. The melanoma SB screen per-
formed by Jenkins, Copeland and colleagues identified
numerous candidate cancer genes, and pathway analysis
found significant enrichment of CIS-associated genes in
many cancer-related signaling pathways, including Wnt/
β-catenin, TGF-β, PI3K and MAPK signaling, as well as in
many biological processes [38]. Recently, it was shown
that, by integrating SB TMIM in mice and mutation ana-
lysis of human cancer genomes, loss of function of the
transcription factor CUX1 drives myeloid malignancy and
other cancer types [20]. It was demonstrated that CUX1
antagonizes the PI3K–AKT signaling pathway by regulat-
ing transcription of the PI3K inhibitor PIK3IP1. Finally, a
SB medulloblastoma screen in Ptch1+/−mice identified
candidate cancer genes and associated protein networks
capable of distinguishing the molecular subgroups of
human medulloblastoma, demonstrating the power of
transposon screens to recapitulate the genetic changes in
human cancer [58].
These studies suggest that pathway and network ana-
lyses can provide insight into mechanisms of human dis-
ease and might predict survival and treatment outcomes.
Thus, TMIM is a powerful approach to unravel the
functional association of altered signaling pathways or
cell-biological processes with cancer development. Con-
ventional sequencing efforts can fail to identify such
associations because the mutation rate of individual
genes regulating these pathways or processes is not
above the background mutation rate. Moreover, al-
though TMIM cannot recapitulate activating mutations
of proto-oncogenes, pathway analyses of TMIM datasets
can reveal the crucial functions downstream of onco-
genes that are commonly mutated in human cancer.
Identification of novel mechanisms of gene deregulation
In cancer cells, loss of mRNA and protein expression
can occur without any obvious genetic alteration in
corresponding protein-coding regions. Notably, recentTMIM studies have identified novel non-coding regula-
tory regions and other mechanisms of gene deregulation
that promote tumorigenesis. For example, a PB screen
identified recurrent transposon insertions in a 200-kb
noncoding region (Ncruc) upstream of the Cdkn2a gene
[32], which encodes the tumor suppressors p16Ink4a
and p19Arf and is frequently inactivated by prototypic
gene-body insertions in both SB and PB pancreatic can-
cer screens [24, 32]. Transposon insertions in or gen-
omic loss of the Ncruc region were associated with
reduced expression levels of Cdkn2a in cis, demonstrat-
ing the power of PB insertional mutagenesis screens to
identify non-coding DNA regions or genes with crucial
roles in tumorigenesis.
Although target-site preferences suggest that PB-based
TMIM screens might be more useful to identify regula-
tory elements compared with SB transposons (Fig. 3),
SB-mediated screens have also been fruitful in identify-
ing atypical mechanisms of gene deregulation in cancer.
For example, Dupuy and colleagues performed a SB-
mediated hepatocellular carcinoma (HCC) screen and
found frequent insertions in the complex imprinted
Dlk1-Dio3 locus. A domesticated retrotransposon, Rtl1,
located in this locus was shown to be overexpressed in
all tumors with Dlk1-Dio3 insertions [59]. Furthermore,
ectopic overexpression of Rtl1 in mouse livers induced
HCC, validating Rtl1 as a novel cancer driver. Examin-
ation of human liver tissue showed that Rtl1 is transcrip-
tionally inactive in normal liver but can be reactivated in
human HCC, supporting a role for Rtl1 in human HCC
development.
In a SB-mediated TMIM screen aimed at identifying
genes that co-operate with oncogenic B-Raf in melan-
oma development, a significant enrichment of genes was
discovered among the CISs that encode mRNAs with
the ability to regulate the expression of the tumor
suppressor Pten [48]. These so-called competitive en-
dogenous RNAs control Pten levels as microRNA de-
coys, in a protein-coding-independent fashion. While
these CIS-associated genes are classical protein-
coding genes, our analysis highlighted a non-coding
function of their mRNAs. Only 2 % of the mamma-
lian genome encodes protein-coding genes; however,
the non-coding portion of the genome, both tran-
scribed (e.g., microRNAs, long non-coding RNAs) and
non-transcribed (e.g., enhancers), plays crucial roles in
physiology and pathology. TMIM screens have barely
scratched the surface of the non-coding space, and
re-analyzing existing SB and PB mutagenesis data
might reveal additional non-coding insertion hotspots.
Identifying mechanisms of resistance to therapy
TMIM has been useful in identifying genes that mediate
therapeutic drug resistance both in vitro and in vivo.
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different human cell lines derived from neuroblastoma,
breast and cervical cancer to identify genes whose
overexpression mediates resistance to paclitaxel [60].
Interestingly, while the authors identified multiple CISs
in the four cell lines, the only CIS that was common to
all four cell lines was the ABCB1 gene [60], which
encodes an ABC-transporter associated with multi-drug
resistance [61]. This suggests the existence of both
cancer-type-specific and common mechanisms of drug
resistance. In addition, Xu and colleagues performed a
PB screen in melanoma cells and identified BRAF and
CRAF as mediators of resistance to the BRAF inhibitor
vemurafenib [62], recapitulating previous observations in
human melanoma patients and cell lines treated with
vemurafenib [63–65].
In diploid cells, biallelic inactivating transposon inser-
tions that completely abrogate gene expression are rare
compared with monoallelic events, thus hampering the
identification of genes that promote drug resistance only
upon complete loss of expression. To tackle this issue,
Ashworth and colleagues [66] took advantage of a
haploid mouse embryonic stem (ES) cell system to
screen for mediators of olaparib toxicity, in which inacti-
vating transposon insertion can result in complete loss
of gene expression. The authors identified the poly
[ADP-ribose] polymerase 1 gene Parp1 as a mediator of
olaparib toxicity, and their results suggested that loss of
Parp1 could result in olaparib resistance in patients [66].
In another mouse ES cell screen, Jonkers and colleagues
identified loss of the gene 53bp1 as a mediator of survival
and DNA-damage responses in Brca1-null cells [67].
Reduced 53BP1 expression was associated with basal-like,
triple-negative, and BRCA1/2-mutant breast cancer in
humans, suggesting that downregulation of 53BP1 might
be an important survival factor in such tumors, par-
ticularly during chemotherapy-induced DNA damage.
These studies demonstrate the utility of TMIM to
identify mediators of resistance in human cancer cell
lines as well as ES cells.
Drug resistance in patients develops in the context of
a supporting microenvironment and, thus, in vitro ap-
proaches might be limited in their ability to identify re-
sistance genes. To avoid this shortcoming of in vitro
drug-resistance screens, a SB screen in a B-RafV600E-
driven mouse model of melanoma was performed. This
identified transposon insertion sites in treatment-naïve
tumors as well as melanomas treated with the vemurafe-
nib progenitor compound PLX4720 [49]. Insertions in
several known mediators of resistance were enriched in
the PLX4720-treated tumors, validating this approach
for resistance gene discovery. An ERAS-AKT-BAD sig-
naling axis was validated as a mediator of drug resist-
ance, which mimics the paracrine mechanism of stromalhepatocyte growth factor-mediated resistance [68, 69].
Curiously, many of the genes that have been previously
identified in cell lines as promoters of resistance through
reactivation of MAPK signaling were not identified in
this in vivo study. A possible explanation is that such
mutations are preexisting in patients only in a minor
tumor subclone that no longer relies on oncogenic
BRAF signaling. Conversely, transposon mobilization
was induced concomitantly with the initiating B-Raf
mutation in the resistance TMIM. In these tumor cells,
transposon insertions that would otherwise result in
MAPK activation might be negatively selected owing to
functional redundancy with oncogenic B-Raf. Thus, add-
itional insight might be gained from studies in which
transposon mobilization is induced at the time of drug
treatment.
Novel approaches of employing transposon mutagenesis
In vivo transposon mutagenesis requires up to four
transgenic alleles to accelerate tumorigenesis in a tissue-
specific manner in a sensitizing background. Generating
and maintaining compound mutant mouse strains is
time consuming and costly, prompting alternative ways
of utilizing the transposon systems. Molyneux and col-
leagues transduced immortalized primary human bone
mesenchymal cells with SB and a lentivirus harboring
the elements of a SB transposon, and, when injected into
mice, the transplanted cells produced myxofibrosarco-
mas [70]. For human candidate cancer gene discovery,
both the insertions of the parental lentivirus as well as
the remobilized transposons were mapped. In another
study, neural stem cells were derived from transgenic
mice harboring the SB system and a Nestin-Cre allele
[71]. Following in vitro differentiation, the neural stem
cells were immortalized through SB mutagenesis and the
resulting immortalized astroglial-like cells were injected
into SCID mice to identify genes that drive glioblastoma
formation. CIS mapping of immortalized cell lines
and tumors identified partially overlapping CISs, sug-
gesting differential roles of the identified genes during
immortalization and tumorigenesis. In vitro delivery
of the transposon system components followed by
orthotopic or subcutaneous transplantation thus repre-
sents another means for in vivo selection and identifica-
tion of candidate cancer genes.
The SB transposon system has also been used as a
reverse-genetics tool to validate candidate cancer genes.
Futreal and colleagues created transposons with both SB
and PB terminal repeats that also harbored IRES-cDNA
cassettes [72], such that the cDNA cargo was expressed
only when transposon insertion occurred in transcribed
genes. Using these transposons, the authors tested
kinases with point mutations encoding putative gain-of-
function oncogenic alleles. Mice were generated carrying
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crossed to SB transgenic mice, leading to tumorigenesis
by in vivo selection of the kinase mutants with the
highest oncogenic potential in somatic cells. This report
elegantly displays how the transposon system can be
utilized to discern the relative oncogenic properties of
several candidate genes simultaneously in all or selected
organs.
To extend the utility of TMIM to another model sys-
tem, transgenic rats carrying the components of the SB
or PB system have been created [73]. The transposons
carried both SB and PB terminal repeats as well as a
tyrosinase expression cassette, permitting coat-color-
based phenotyping for transposon zygosity and genomic
position effects on tyrosinase expression in albino rat
backgrounds. In the future, it will be interesting to deter-
mine the overlap in cancer genes identified by TMIM
screens in mouse and rat and their relevance to human
cancer.
Comparison with other technologies
Other methods of forward-genetic screens for the pro-
motion of tumorigenesis and related phenotypes in vivo
include the use of cDNA or short hairpin RNA (shRNA)
libraries for gain-of-function or loss-of-function screens,
respectively. In addition, the CRISPR/Cas9 system, a
novel powerful tool for genome editing [74, 75], can be
employed for gain-of-function and loss-of-function
screens. The conventional CRISPR/Cas9 system uses a
short guide RNA (sgRNA) to direct the Cas9 DNA
endonuclease to a complementary DNA target, resulting
in double-strand DNA cleavage, which can result in
loss-of-function frameshift indels within exons when
DNA breaks are repaired by error-prone non-
homologous end-joining mechanisms. Alternative Cas9
enzymes, lacking endonuclease activity, have been engi-
neered that promote transcriptional repression [76, 77]
or activation [78–80] of target genes when coexpressed
with targeting sgRNAs. These approaches have several
advantages and disadvantages compared with TMIM,
and the different approaches thus provide complemen-
tary technologies for cancer gene discovery (Table 2).
One major pitfall of shRNA, cDNA and CRISPR/Cas9
screens is that these approaches allow for identification
of either tumor suppressors or oncogenes, but not both
at the same time [78, 81]. By contrast, TMIM has the
ability to detect both tumor suppressors and oncogenes
simultaneously owing to the genetic elements within the
transposons that intercept and promote transcription
(see discussion above). Comprehensive shRNA [82–85],
sgRNA [78, 86–89] and cDNA [90] libraries have been
created for forward-genetic screens. However, the task of
delivery of these libraries to the cell type of interest for
in vivo screens is not trivial. Usually, libraries aredelivered in vitro, followed by orthotopic or subcutane-
ous transplantation of the library-infected cells [91].
While this can be a viable approach in many cases, it
might not always accurately recapitulate tumor progres-
sion in its natural environment [92] and might therefore
select for false-positive candidate cancer genes. In
addition, delivery of libraries with lentiviruses can cause
tumor-promoting insertional mutagenesis [93, 94] that
remains undetected unless these insertion sites are
mapped in conjunction with shRNA/sgRNA/cDNA
identification. TMIM does not face the issue of library
delivery as the transposons are already included in the
genome of transgenic mouse strains, and transposon
mobilization is readily achieved in virtually any cell
type. However, owing to the local hopping effect [34]
observed in TMIM, the donor chromosome contain-
ing the parental transposon concatemer has to be
excluded from the analysis. Thus, to probe all chro-
mosomes by TMIM, more than one transposon
mouse strain has to be used [31].
Another bias of shRNA and CRISPR/Cas9 screens is
that shRNAs and sgRNAs are designed to target specific
sequences. Thus, these screens are inherently biased, al-
though whether this impacts candidate cancer gene dis-
covery remains to be determined. Moreover, while
shRNA and sgRNA design algorithms generate se-
quences with minimal predicted off-target effects, such
effects cannot be excluded experimentally [78, 81, 88,
89, 95–99]. To control for off-target effects by shRNA
and sgRNAs, bona fide hits need to be identified by
more than one shRNA or sgRNA. In TMIM, the
number of transposon insertion sites in a predefined
genomic window determines the statistical significance
of a CIS [39–41, 43]. However, owing to the contin-
ued hopping of unselected transposons and the con-
sequential heterogeneity of tumors with hundreds of
passenger insertions, accurate CIS calling remains
challenging. Not only are bona fide candidate cancer
genes excluded and false positives included following
the statistical analysis, CISs might also affect more
than one gene. Thus, proper functional validation of
any candidates identified by these screening methods
is an absolute requirement.
Current sgRNA, shRNA and cDNA libraries are fairly
comprehensive, but they do not yet match the ability of
TMIM to query virtually the entire genome. However, it
is difficult to identify small genetic entities such as
microRNAs and enhancers because the likelihood of
transposon insertions in the precise locations that would
affect their expression or activity is lower. With the
CRISPR/Cas9 system, these genes and genetic ele-
ments can be targeted and inactivated directly. In-
deed, commercially available CRISPR/Cas9 libraries
already contain sgRNAs targeting microRNAs [86],
Table 2 Comparison of genome-wide TMIM, CRISPR/Cas9 and shRNA/cDNA expression technologies
Feature TMIM CRISPR/Cas9 shRNA and cDNA libraries
Screen set-up Two-component system (transposase
and transposon)
Comprehensive delivery of libraries
can be technically challenging
Comprehensive delivery of libraries
can be technically challenging
Possible types of mutation Activating and disruptive mutations











Mutations either can (transcription
repression [76, 77] and activation
[79, 80] libraries) or cannot be
reversed (knockout libraries)
Mutations can be reversed following
transposon remobilization
Mutagenesis efficiency Biallelic gene inactivation rare in
diploid cells
Biallelic mutation achievable with
knockout libraries [88] and 90–99 %
knockdown efficiency achievable
with repression libraries [89]
≥70 % gene knockdown with
validated shRNA clones [82–84]
>2 standard deviation overexpression
by 90 % of cDNA expression
vectors [90]
Undesired and off-target effects Local hopping effects [31],
passenger insertions
Minimal off-target effects
[78, 81, 88, 89, 95, 96]
Off-target effects can be significant
[97–99]
Viral-associated insertional
mutagenesis possible [93, 94]
Viral-associated insertional mutagenesis
possible [93, 94]




Dictated by library design Dictated by library design
Knockout libraries ~8000 human, ~15,000 mouse genes
(NKI shRNA library) [85]; >20,000 human
and mouse genes (TRC shRNA library)
[82, 83]; ~60,000 human and mouse
genes (Hannon–Elledge shRNA library)
[84]; >17,000 human genes (cDNA
expression library) [90]
GeCKOv2 [86]: ~20,000 genes,
1000–2000 miRNAs for human
and mouse. Koike-Yusa et al.
[87]: ~20,000 mouse genes.
Wang et al. [88]: ~7000
human genes
CRISPR-activation libraries
CRISPRa [89]: ~16,000 human




NKI Netherlands Cancer Institute, shRNA short hairpin RNA, TMIM transposon-mediated insertional mutagenesis, TRC The RNAi Consortium
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surely be developed in the near future. Another con-
sideration is that complete target repression is not
achieved by either shRNA or TMIM. shRNAs vary
drastically in their ability to repress target mRNAs,
and transposon insertion is typically observed in only
one allele. These technologies are thus biased towards
the identification of candidate cancer genes whose in-
complete repression promotes tumorigenesis, such as
haploinsufficient tumor suppressors or tumor sup-
pressors that readily undergo loss-of-heterozygosity.
Conversely, the CRISPR/Cas9 system readily generates
biallelic deletions [88, 100] and is therefore able to
discover genes that will yield phenotypes only after
homozygous loss. Thus, genome coverage and gene
dosage are important considerations when choosing a
screening system.Finally, insertions and deletions introduced by the
CRISPR/Cas9 system occur through error-prone non-
homologous end joining [75]. It is therefore possible that
in-frame indels are generated that do not abrogate protein
expression [87] but alter proper biological function. This,
in turn, could yield different phenotypes compared with
those arising from the absence of the protein and could
affect the outcome and/or interpretation of the screen. In-
frame indels will be selected for if they provide a biological
advantage, and are therefore distinguishable from indels
that result in frameshifts. Such in-frame indels might re-
veal interesting aspects about the biology of certain pro-
teins; however, their relevance to human disease will have
to be determined on a case-by-case basis. In summary, the
different technologies for forward-genetic screening have
various pros and cons that need to be considered when
designing a screen experiment.
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The past few years have brought remarkable advances in
the field of transposon-mediated insertional mutagen-
esis. First, technological developments have enabled in-
vestigators to identify cancer genes in an ever-expanding
array of cell types and at various stages of tumor evolu-
tion. Second, improvements to bioinformatics and statis-
tical methods ensure the identification of crucial cancer
genes and pathways and the exclusion of false-positive
hits. Third, the vastly increased availability of genomic
and mutational data from human cancer specimens
allows for the comparison of such data with TMIM
results, thereby distinguishing genes with relevance to
human cancer that were identified in mice. TMIM re-
mains relevant in the age of CRISPR/Cas9 screens, and
together these technologies form a powerful and com-
plementary toolbox to query the genome for the genetic
causes of cancer.
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